<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260125068657N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-02-27</date_registration>
      <primary_sponsor>Razi University</primary_sponsor>
      <public_title>The Effect of 12-Week Aerobic Training Combined with a Low-Sodium Diet on Blood Pressure and Pulmonary Function in Obese Elderly Adults with Hypertension</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of 12 week of Aerobic Exercise Combined with a Low-Sodium Diet on Blood Pressure and Pulmonary Function in Obese Elderly Individuals with Hypertension</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-03-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/88943</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Eligible participants, after completing the baseline assessment, will be randomly assigned to either the "intervention" or "control" group. The randomization process will be performed using a **block randomization** method with blocks of four, and will be stratified based on **treatment center** and **disease severity** (stratified randomization). The unit of randomization in this study is the individual.
The random allocation sequence will be generated by an individual not involved in the trial's execution, using SAS statistical software (version 9.4). To ensure allocation concealment, the group assignment for each participant will be placed inside sequentially numbered, opaque, sealed envelopes. These envelopes will only be opened by the researcher after a participant's final eligibility is confirmed and at the moment of enrollment in the study.
The detailed procedure for randomization is as follows: first, the list of eligible participants will be categorized based on the strata (center and disease severity). Then, for each stratum separately, blocks of four with a specific random sequence (maintaining a 1:1 ratio for intervention and control groups) will be generated by the software. These assignments will be placed in the numbered envelopes and distributed to the centers. Using this method, both the researcher and the participant remain unaware of the next group assignment until after the allocation is finalized, thereby minimizing selection bias, Blinding description: This study will employ a single-blind design. The participants will be blinded to their group allocation (intervention or control). Exercise trainers and clinical assessors will not be blinded to the intervention type, but all efforts will be made to standardize interactions with both groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Hypertension.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Combined Group; Receives aerobic exercise (3 sessions/week, 12 weeks) combined with a low-sodium diet (&lt;2g sodium/day). Intervention 2: Intervention group: Exercise Group; Receives only the aerobic exercise program. Intervention 3: Intervention group: Diet Group; Receives only the low-sodium diet. Intervention 4: Control group: Receives usual care without the specific exercise or dietary intervention of this study.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data will be recorded in the SPSS software and will be available

When:
Availability will start nine months after publishing all papers

To whom:
Only available for researchers in academic and scientific institutions

Conditions:
All data can be used as a reference

Where to obtain:
sahelveiskarami93@gmail.com

How to obtain:
If the explanation for the data request would be convincing it will be given in 3 days.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Rastegar Hoseini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 9, Razi University, Daneshgah Boulevard, Taq Bostan Street, Kermanshah City</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6714967346</zip>
        <telephone>+98 83 3428 3270</telephone>
        <email>R.hoseini@razi.ac.ir</email>
        <affiliation>Razi University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sahel Viskaremi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 9, Razi University, Daneshgah Boulevard, Taq Bostan Street, Kermanshah City</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6714967346</zip>
        <telephone>+98 83 3428 3270</telephone>
        <email>sahelveiskarami93@gmail.com</email>
        <affiliation>Razi Univeristy</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age ≥ 60 years, and provision of informed consent.
Obesity (BMI ≥ 30 kg/m²)
stage 1 or 2 hypertension on stable pharmacological treatment
Medical clearance for moderate-intensity exercise
Absence of acute cardio-pulmonary diseases
No regular participation in structured exercise programs or a low-sodium diet in the past 6 months</inclusion_criteria>
      <agemin>60 years</agemin>
      <agemax>75 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Serious or uncontrolled comorbidities (e.g., cardiovascular, pulmonary, renal, or diabetes).
Use of medications affecting blood pressure or body weight (other than stable antihypertensive therapy)
Having severe orthopedic limitations
Active smoking within the past year</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I27.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other secondary pulmonary hypertension</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Combined Group; Receives aerobic exercise (3 sessions/week, 12 weeks) combined with a low-sodium diet (&lt;2g sodium/day)</i_keyword>
      <i_keyword>Intervention group: Exercise Group; Receives only the aerobic exercise program.</i_keyword>
      <i_keyword>Intervention group: Diet Group; Receives only the low-sodium diet.</i_keyword>
      <i_keyword>Control group: Receives usual care without the specific exercise or dietary intervention of this study.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Systolic and Diastolic Blood Pressure. Timepoint: Study baseline, Week 6, and post-intervention at Week 12. Method of measurement: Measured using a calibrated digital sphygmomanometer after 5 minutes of seated rest.</prim_outcome>
      <prim_outcome>Forced Expiratory Volume in 1 second (FEV1). Timepoint: Study baseline and post-intervention at Week 12. Method of measurement: Measured using a spirometer according to standard ATS/ERS guidelines.</prim_outcome>
      <prim_outcome>Forced Vital Capacity (FVC). Timepoint: Study baseline and post-intervention at Week 12. Method of measurement: Measured using a spirometer according to standard ATS/ERS guidelines.</prim_outcome>
      <prim_outcome>FEV1/FVC Ratio. Timepoint: Study baseline and post-intervention at Week 12. Method of measurement: Measured using a spirometer according to standard ATS/ERS guidelines.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Razi University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-12-29</approval_date>
        <contact_name>Research Ethics Committees of Kermanshah Razi University</contact_name>
        <contact_address>No. 8, Razi University, Daneshgah Boulevard, Taq Bostan Street, Kermanshah, Iran Kermanshah Kermanshah Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
